Observational studyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Of the manuscript: relationship between serum Zonulin level and sarcopenia in Parkinson's disease.
Observational study in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate serum zonulin levels, an intestinal permeability marker, in Parkinson's disease (PD) patients and explore its relationships with sarcopenia, motor subtypes, clinical features, and age- and sex-matched controls.
methodsThis observational cross-sectional study evaluated 119 participants (64 with PD, 55 controls). Demographic data, along with disease duration, comorbidities, and motor subtypes, were documented. Handgrip strength and skeletal muscle mass index (SMMI) were used to assess sarcopenia, with SMMI determined by bioelectrical impedance analysis and adjusted for BMI using Turkish-specific cut-offs. Serum zonulin levels were assessed via ELISA.
resultsCompared to controls, zonulin levels were generally increased in PD patients; however, the difference was statistically insignificant (p = 0.289). Zonulin levels, though, varied notably across PD motor subtypes, with mixed-type showing the highest median levels (p = 0.004). The PD group had a significantly higher sarcopenia prevalence (73.4%) than the control group (53.7%), and longer disease duration was associated with sarcopenia (p = 0.014). There was no significant difference in zonulin levels between sarcopenic and non-sarcopenic individuals.
conclusionZonulin serum levels seem to differ based on PD motor subtype, which implies that gut permeability might influence phenotypic expression. The connection between sarcopenia, common in PD and related to disease duration, and its direct association with zonulin remains unclear. Future research should investigate gut-muscle-brain connections in longitudinal designs and evaluate whether interventions targeting intestinal permeability are associated with, rather than directly modifying, clinical outcomes in PD.
Indexed as
Identifiers
41535544What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.